| scholarly article | Q13442814 |
| P2093 | author name string | Ben Vainer | |
| Fin Stolze Larsen | |||
| Bent Adel Hansen | |||
| Martin Eefsen | |||
| Peter Nissen Bjerring | |||
| P2860 | cites work | Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups | Q29614459 |
| An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group | Q29614898 | ||
| Histological grading and staging of chronic hepatitis | Q29619625 | ||
| Autoimmune hepatitis, from mechanisms to therapy | Q33342074 | ||
| International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis | Q33784003 | ||
| Current and novel immunosuppressive therapy for autoimmune hepatitis | Q34490185 | ||
| Late results of the Royal Free Hospital prospective controlled trial of prednisolone therapy in hepatitis B surface antigen negative chronic active hepatitis | Q34494662 | ||
| Tacrolimus: a potential new treatment for autoimmune chronic active hepatitis: results of an open-label preliminary trial | Q34498312 | ||
| Efficacy of tacrolimus in the treatment of steroid refractory autoimmune hepatitis | Q45057464 | ||
| Short-term cyclosporine induces a remission of autoimmune hepatitis in children. | Q53347844 | ||
| Mycophenolate mofetil for maintenance of remission in autoimmune hepatitis in patients resistant to or intolerant of azathioprine. | Q54034536 | ||
| Autoimmune Hepatitis | Q56210456 | ||
| Autoimmune hepatitis: the investigational and clinical challenges | Q73746129 | ||
| Decreased fibrosis during corticosteroid therapy of autoimmune hepatitis | Q79798205 | ||
| P433 | issue | 23 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 3232-3236 | |
| P577 | publication date | 2007-06-01 | |
| P1433 | published in | World Journal of Gastroenterology | Q15708885 |
| P1476 | title | Low-dose tacrolimus ameliorates liver inflammation and fibrosis in steroid refractory autoimmune hepatitis | |
| P478 | volume | 13 |
| Q38054513 | Acute and acute severe (fulminant) autoimmune hepatitis |
| Q38720387 | Acute-on-chronic liver failure: terminology, mechanisms and management |
| Q26746242 | Auto immune hepatitis |
| Q55040971 | Autoimmune Hepatitis in the Asia-Pacific Area. |
| Q92314377 | Autoimmune Hepatitis-Immunologically Triggered Liver Pathogenesis-Diagnostic and Therapeutic Strategies |
| Q35906055 | Autoimmune Hepatitis: Clinical Review with Insights into the Purinergic Mechanism of Disease |
| Q36490242 | Autoimmune hepatitis as a unique form of an autoimmune liver disease: immunological aspects and clinical overview |
| Q60932817 | Autoimmune hepatitis: Appraisal of current treatment guidelines |
| Q42358509 | Autoimmune hepatitis: Standard treatment and systematic review of alternative treatments |
| Q36231841 | Autoimmune hepatitis: focusing on treatments other than steroids |
| Q37924059 | Budesonide for the treatment of autoimmune hepatitis |
| Q22305507 | Clinical features and management of autoimmune hepatitis |
| Q34292354 | Combining ZHENG Theory and High-Throughput Expression Data to Predict New Effects of Chinese Herbal Formulae |
| Q38222882 | Current and prospective pharmacotherapy for autoimmune hepatitis |
| Q38609184 | Current concepts in the diagnosis and management of autoimmune hepatitis |
| Q34408950 | Current status of therapy in autoimmune liver disease |
| Q28076505 | Diagnosis and Management of Autoimmune Hepatitis: Current Status and Future Directions |
| Q33688293 | Difficult treatment decisions in autoimmune hepatitis |
| Q51596178 | Early predictors of corticosteroid treatment failure in icteric presentations of autoimmune hepatitis. |
| Q41344505 | Everolimus treatment for patients with autoimmune hepatitis and poor response to standard therapy and drug alternatives in use. |
| Q38779430 | Expert clinical management of autoimmune hepatitis in the real world |
| Q57928162 | Flare of Autoimmune Hepatitis causing acute on chronic liver failure (ACLF): diagnosis and response to corticosteroid therapy |
| Q59355703 | Harmful Effects and Potential Benefits of Anti-Tumor Necrosis Factor (TNF)-α on the Liver |
| Q38930837 | Immunosuppressive drugs affect interferon (IFN)-γ and programmed cell death 1 (PD-1) kinetics in patients with newly diagnosed autoimmune hepatitis. |
| Q26859099 | Management of autoimmune hepatitis: Focus on pharmacologic treatments beyond corticosteroids |
| Q36379083 | Management of patients with difficult autoimmune hepatitis |
| Q46198163 | Mycophenolate mofetil for autoimmune hepatitis: a single practice experience |
| Q33447479 | Non-classical phenotypes of autoimmune hepatitis and advances in diagnosis and treatment. |
| Q37492725 | Outcomes in pediatric autoimmune hepatitis |
| Q37828507 | Pharmacological management of autoimmune hepatitis |
| Q46408372 | Refractory Autoimmune Hepatitis: Beyond Standard Therapy |
| Q38175465 | Review article: The prevention and reversal of hepatic fibrosis in autoimmune hepatitis |
| Q38027909 | Review article: overlap syndromes and autoimmune liver disease |
| Q26864272 | Review article: the management of autoimmune hepatitis beyond consensus guidelines |
| Q34299536 | Systematic review: managing suboptimal treatment responses in autoimmune hepatitis with conventional and nonstandard drugs. |
| Q52641231 | Tacrolimus and Mycophenolate Mofetil as Second-Line Therapies for Pediatric Patients with Autoimmune Hepatitis. |
| Q92940532 | The Contribution of B Cells in Autoimmune Liver Diseases |
| Q34149523 | Treatment of autoimmune hepatitis: A review of current and evolving therapies |
| Q34342199 | Treatment of autoimmune liver disease: current and future therapeutic options |
Search more.